Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.38M$4.38Mderived+19.9% vs Q4 2018 Net Income-$3.22M-$3.22MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,875,000+40.8% Operating Incomederived-$2,704,000N/M Operating Cash Flowderived-$2,746,000N/M Free Cash Flowderived-$2,760,000N/M Margins · derivedGross margin42.8%+6.3 pt vs Q4 2018
Operating margin-61.7%+68.2 pt vs Q4 2018
Net margin-73.5%+56.8 pt vs Q4 2018
ended Mar 31, 2019 · filed Jul 1, 2019 · 92 d after period end